Abenhaim L, Moride Y, Brenot F et al (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. N Engl J Med 335:609–616
PubMedCrossRefAbraham WT, Stevenson LW, Bourge RC, Lindenfeld JA, Bauman JG, Adamson PB, CHAMPION Trial Study Group (2016) Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial. Lancet 387:453–461
PubMedCrossRefAlabed S, Shahin Y, Garg P, Alandejani F, Johns CS, Lewis RA et al (2021) Cardiac-MRI predicts clinical worsening and mortality in pulmonary arterial hypertension: a systematic review and meta-analysis. JACC Cardiovasc Imaging 14:931–942
PubMedPubMedCentralCrossRefAßmus B, Angermann CE, Alkhlout B et al (2022) Treatment response to heart failure management guided by remote pulmonary-artery-pressure-monitoring depends on presence and severity of pulmonary hypertension. Eur J Heart Fail 24:2320–2330. Epub ahead of print
Boucly A, Savale L, Jaïs X et al (2021) Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 204:842–854
PubMedCrossRefBoucly A, Weatherald J, Savale L et al (2022) External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry. Eur Respir J 59(6):2102419
PubMedPubMedCentralCrossRefBudev MM, Arroliga AC, Wiedemann HP, Matthay RA (2003) Cor pulmonale: an overview. Semin Respir Crit Care Med 24:233–244
PubMedCrossRefChin K, Sitbon O, Doelberg M et al (2021) Three- versus two-drug therapy for patients with newly diagnosed pulmonary arterial hypertension. J Am Coll Cardiol 78:1393–1403
PubMedCrossRefChin KM, Rubin LJ, Channick R, Di Scala L, Gaine S, Galiè N et al (2019) Association of N-terminal pro brain natriuretic peptide and long-term outcome in patients with pulmonary arterial hypertension. Insights From the Phase III GRIPHON Study. Circulation 139:2440–2450
PubMedPubMedCentralCrossRefCoghlan JG, Wolf M, Distler O, Denton CP, Doelberg M, Harutyunova S et al (2018) Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 51:1701197
PubMedCrossRefD’Alonzo GE, Barst RJ, Ayres SM et al (1991) Survival in patients with primary pulmonary hypertension. Ann Intern Med 115:343–349
PubMedCrossRefDelcroix M, Torbicki A, Gopalan D et al (2021) ERS statement on chronic thrombo-embolic pulmonary hypertension. Eur Respir J 57(6):2002828
PubMedCrossRefDimopoulos K, Inuzuka R, Goletto S et al (2010) Improved survival among patients with Eisenmenger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 121:20–25
Dumitrescu D, Nagel C, Kovacs G, Bollmann T, Halank M, Winkler J et al (2017) Cardiopulmonary exercise testing for detecting pulmonary arterial hypertension in systemic sclerosis. Heart 103:774–782
PubMedCrossRefEyries M, Montani D, Girerd B, Perret C, Leroy A, Lonjou C et al (2014) EIF2AK4 mutations cause pulmonary veno-occlusive disease, a recessive form of pulmonary hypertension. Nat Genet 46:65–69
PubMedCrossRefFauvel C, Raitiere O, Boucly A, de Groote P, Renard S, Bertona J et al (2022) Interest of TAPSE/sPAP ratio for noninvasive pulmonary arterial hypertension risk assessment. J Heart Lung Transplant 41:1761–1772
PubMedCrossRefGaine S (2000) Pulmonary hypertension. JAMA 284:3160–3168
Galiè N, Ghofrani HA, Torbicki A et al, for the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353: 21482157
Galiè N, Brundage BH, Ghofrani HA et al, for the PHIRST Investigators (2009) Tadalafil therapy for pulmonary arterial hypertension. Circulation 119:2894–2903
Galiè N, Barbera JA, Frost A et al (2015) Initial use of Ambrisentan plus Tadalafil in pulmonary arterial hypertension. New Engl J Med 379:834–844
CrossRefGaliè N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 37:67–119
PubMedCrossRefGhofrani HA, D’Armini AM, Grimminger F et al, for the CHEST Investigators (2013a) Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 369:319–329
Ghofrani HA, Galiè N, Grimminger F et al, for the PATENT Investigators (2013b) Riociguat for the treatment of pulmonary arterial hypertension. N Engl J Med 369:330–340
Guazzi M, Naeije R (2017) Pulmonary hypertension in heart failure: pathophysiology, pathobiology, and emerging clinical perspectives. J Am Coll Cardiol 69:1718–1734
PubMedCrossRefGuazzi M, Vicenzi M, Arena R, Guazzi MD (2011) Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study. Circulation 124:164–174
PubMedCrossRefHachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D et al (2018) Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French Pulmonary Hypertension Registry. Chest 153:143–151
PubMedCrossRefHarris P, Heath D (1986) The structure of the normal pulmonary blood vessels after infancy. In: Harris P, Heath D (Hrsg) The human circulation: its form and function in health and disease. Churchill-Livingstone, Edinburgh, S 30–47
Hoendermis E, Liu LCY, Hummel YM et al (2015) Effects of sildenafil on invasive hemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. Eur Heart J 36:2565–2573
PubMedCrossRefHoeper MM, Pletz MW, Golpon H, Welte T (2007) Prognostic value of blood gas analyses in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 29:944–950
PubMedCrossRefHoeper MM, Ghofrani HA, Al-Hiti H et al, on behalf of the REPLACE investigators (2021) Switching from phosphodiesterase-5 inhibitors to riociguat in patients with pulmonary arterial hypertension: results from the REPLACE study. Lancet Respir Med 9:573–584
Hoeper MM, Dwivedi K, Pausch C et al (2022a) Phenotyping of idiopathic pulmonary arterial hypertension: a registry analysis. Lancet Respir Med 10:937–948
PubMedPubMedCentralCrossRefHoeper MM, Pausch C, Olsson KM et al (2022b) COMPERA 2.0: a refined 4-strata risk assessment model for pulmonary arterial hypertension. Eur Respir J 60(1):2102311
PubMedPubMedCentralCrossRefHoeper MM, Badesch DB, Ghofrani HA, Gibbs JSR, Gomberg-Maitland M, McLaughlin VV et al, for the STELLAR Trial Investigators (2023) A phase 3 trial of Sotatercept for the treatment of pulmonary arterial hypertension. N Eng J Med 388:1478–1490
Humbert M, Guignabert C, Bonnet S et al (2019) Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives. Eur Respir J 53(1):pii: 1801887
CrossRefHumbert M, McLaughlin V, Gibbs JSR, Gomberg-Maitland M, Hoeper MM, Preston IR et al, PULSAR Trial Investigators (2021) Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med 384:1204–1215
Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731
PubMedCrossRefJaïs X, Brenot P, Bouvaist H, Jevnikar M, Canuet M, Chabanne C et al (2022) Balloon pulmonary angioplasty versus riociguat for the treatment of inoperable chronic thromboembolic pulmonary hypertension (RACE): a multicentre, phase 3, open-label, randomised controlled trial and ancillary follow-up study. Lancet Respir Med 10:961–971
PubMedCrossRefKinsella JP, Abman SH (1995) Recent developments in the pathophysiology and treatment of persistent pulmonary hypertension of the newborn. J Pediatr 126:853–864
PubMedCrossRefKovacs G, Berghold A, Scheidl S, Olschewski H (2009) Pulmonary arterial pressure during rest and exercise in healthy subjects. A systematic review. Eur Respir J 34:888–894
PubMedCrossRefKrowka MJ, Fallon MB, Kawut SM, Fuhrmann V, Heimbach JK, Ramsay MA et al (2016) International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension. Transplantation 100:1440–1452
PubMedCrossRefLammers AE, Bauer LJ, Diller GP, Helm PC, Abdul-Khaliq H, Bauer UMM et al (2020) Pulmonary hypertension after shunt closure in patients with simple congenital heart defects. Int J Cardiol 308:28–32
PubMedCrossRefLau EMT, Giannoulatou E, Celermajer DS, Humbert M (2017) Epidemiology and treatment of pulmonary arterial hypertension. Nat Rev Cardiol 14:603–614
PubMedCrossRefLaunay D, Montani D, Hassoun PM, Cottin V, Le Pavec J, Clerson P et al (2018) Clinical phenotypes and survival of pre-capillary pulmonary hypertension in systemic sclerosis. PLoS One 13:e0197112
PubMedPubMedCentralCrossRefLeber L, Beaudet A, Muller A (2021) Epidemiology of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: identification of the most accurate estimates from a systematic literature review. Pulm Circ 11:2045894020977300
PubMedPubMedCentralCrossRefLewis RA, Johns CS, Cogliano M, Capener D, Tubman E, Elliot CA et al (2020) Identification of cardiac magnetic resonance imaging thresholds for risk stratification in pulmonary arterial hypertension. Am J Respir Crit Care Med 201:458–468
PubMedPubMedCentralCrossRefLopez-Sendon J, Sanchez MAG, De Juan MJM, Coma-Canella I (1990) Pulmonary hypertension in the toxic oil syndrome. In: Fishman AP (Hrsg) The pulmonary circulation: normal and abnormal. University of Pennsylvania Press, Philadelphia, S 385–396
CrossRefMahmut E, Madani MM, Kim NH et al (2018) Chronic thromboembolic pulmonary hypertension: evolving therapeutic approaches for operable and inoperable disease. J Am Coll Cardiol 71:2468–2486
Marecki JC, Cool CD, Parr JE et al (2006) HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med 174:437–445
PubMedPubMedCentralCrossRefMaron BA, Hess E, Maddox TM et al (2016) Association of borderline pulmonary hypertension with mortality and hospitalization in a large patient cohort: insights from the Veterans Affairs clinical assessment, reporting, and tracking program. Circulation 133:1240–1248
PubMedPubMedCentralCrossRefMaron BA, Brittain EL, Hess E et al (2020) Pulmonary vascular resistance and clinical outcomes in patients with pulmonary hypertension: a retrospective cohort study. Lancet Respir Med 8:873–884
PubMedPubMedCentralCrossRefMcLaughlin VV, Vachiery JL, Oudiz R et al (2019) Patients with pulmonary arterial hypertension with and without cardiovascular risk factors: results from the AMBITION trial. J Heart Lung Transplant 38:1286–1295
PubMedCrossRefMontani D, Lau EM, Dorfmuller P, Girerd B, Jais X, Savale L et al (2016) Pulmonary veno-occlusive disease. Eur Respir J 47:1518–1534
PubMedCrossRefMorrell NW, Aldred MA, Chung WJ et al (2019) Genetics and genomics in pulmonary arterial hypertension. Eur Respir J 58:1801899
CrossRefMoser B, Jaksch P, Taghavi S, Murakozy G, Lang G, Hager H et al (2018) Lung transplantation for idiopathic pulmonary arterial hypertension on intraoperative and postoperatively prolonged extracorporeal membrane oxygenation provides optimally controlled reperfusion and excellent outcome. Eur J Cardiothorac Surg 53:178–185
PubMedCrossRefNathan SD, Barbera JA, Gaine SP et al (2019) Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J 53(1):1801914
PubMedPubMedCentralCrossRefOlschewski A, Weir EK (2004) Hypoxic pulmonary vasoconstriction and hypertension. In: Peacock AJ, Rubin LJ (Hrsg) Pulmonary circulation. Arnold/Oxford University Press, London, S 33–44
Olschewski A, Berghausen EM, Eichstaedt CA et al (2018) Pathobiology, pathology and genetics of pulmonary hypertension: update from the Cologne Consensus Conference 2018. Int J Cardiol 272S:4–10
PubMedCrossRefOpitz CF, Hoeper MM, Gibbs JSR et al (2016) Pre-capillary, combined, and post-capillary pulmonary hypertension: a pathophysiological continuum. J Am Coll Cardiol 68:368–378
PubMedCrossRefPulido T, Adzerikho I, Channick RN et al, for the SERAPHIN Investigators (2013) Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 369:809–818
Rich S, Dantzker DR, Ayres SM et al (1987) Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107:216–223
Riel AC van, Schuuring MJ, van Hessen ID, Zwinderman AH, Cozijnsen L, Reichert CL et al (2014) Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification. Int J Cardiol 174:299–305
Rosenkranz S, Gibbs JSR, Wachter R, De Marco T, Vonk-Noordegraaf A, Vachiéry JL (2016) Left ventricular heart failure and pulmonary hypertension. Eur Heart J 37:942–954
PubMedCrossRefRosenkranz S, Howard LS, Gomberg-Maitland M, Hoeper MM (2020) Systemic consequences of pulmonary hypertension and right heart failure. Circulation 141:678–693
PubMedCrossRefRosenkranz S, Channick R, Chin KM, Jenner B, Gaine S, Galiè N et al (2022) Impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study. Eur J Heart Fail 24:205–214
PubMedCrossRefRosenkranz S, Pausch C, Coghlan JG et al (2023) Risk stratification and response to therapy in patients with pulmonary arterial hypertension and comorbidities: a COMPERA analysis. J Heart Lung Transplant 42:102–114
PubMedCrossRefRudski LG, Lai WW, Afilalo J et al (2010) Guidelines for the échocardiographie assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 23:685–713
PubMedCrossRefSadushi-Kolici R, Jansa P, Kopec G, Torbicki A, Skoro-Sajer N, Campean IA et al (2019) Subcutaneous treprostinil for the treatment of severe non-operable chronic thromboembolic pulmonary hypertension (CTREPH): a double-blind, phase 3, randomised controlled trial. Lancet Respir Med 7:239–248
PubMedCrossRefSavale L, Guimas M, Ebstein N, Fertin M, Jevnikar M, Renard S et al (2020) Portopulmonary hypertension in the current era of pulmonary hypertension management. J Hepatol 73:130–139
PubMedCrossRefSitbon O, Humbert M, Jais X et al (2005) Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 111:3105–3111
PubMedCrossRefSitbon O, Lascoux-Combe C, Delfraissy JF et al (2008) Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med 177:108–113
PubMedCrossRefSitbon O, Channick R, Chin KM et al, GRIPHON Investigators (2015) Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med 373:2522–2533
Tongers J, Schwerdtfeger B, Klein G et al (2007) Incidence and clinical relevance of supraventricular tachyarrhythmias in pulmonary hypertension. Am Heart J 153:127–132
PubMedCrossRefTunariu N, Gibbs SJ, Win Z et al (2007) Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 48:680–684
PubMedCrossRefValerio L, Mavromanoli AC, Barco S, et al, on behalf of the FOCUS Investigators (2022) Implications of persistent functional impairment after acute pulmonary embolism: FOCUS, a prospective multicentre observational cohort study. Eur Heart J 43:3387–3398
Vanderpool RR, Saul M, Nouraie M et al (2018) Association between hemodynamic markers of pulmonary hypertension and outcomes in patients with heart failure and preserved ejection fraction. JAMA Cardiol 3:298–306
PubMedPubMedCentralCrossRefWasserman K, Hansen JE, Sue DY et al (Hrsg) (2004) Principles of exercise testing and interpretation, 4. Aufl. Lippincott Williams & Wilkins, Philadelphia
Waxman A, Restrepo-Jaramillo R, Thenappan T et al (2021) Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med 384:325–334
PubMedCrossRefWeatherald J, Montani D, Jevnikar M, Jais X, Savale L, Humbert M (2019) Screening for pulmonary arterial hypertension in systemic sclerosis. Eur Respir Rev 28:190023
PubMedPubMedCentralCrossRefYasunobu Y, Oudiz RJ, Sun XG et al (2005) End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest 127:1637–1646
PubMedCrossRefYusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Goldfarb SB et al (2015) The Registry of the International Society for Heart and Lung Transplantation: thirty-second official adult lung and heart-lung transplantation report – 2015; focus theme: early graft failure. J Heart Lung Transplant 34:1264–1277
PubMedCrossRefZeder K, Banfi C, Steinrisser-Allex G et al (2022) Diagnostic, prognostic and differential-diagnostic relevance of pulmonary haemodynamic parameters during exercise: a systematic review. Eur Respir J 60(4):2103181
PubMedPubMedCentralCrossRef